Instil Bio, Inc. (TIL)

$5.06

-0.24 (-4.53%)
Rating:
Recommendation:
-
Symbol TIL
Price $5.06
Beta 0.334
Volume Avg. 0.34M
Market Cap 656.252M
Shares () -
52 Week Range 3.9-23.215
1y Target Est -
DCF Unlevered TIL DCF ->
DCF Levered TIL LDCF ->
ROE -29.41% Sell
ROA -27.46% Sell
Operating Margin -
Debt / Equity 24.04% Neutral
P/E -
P/B 1.43 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TIL news


None
Healthcare
Biotechnology
NASDAQ Global Select

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.